These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9626341)

  • 1. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients.
    Torrisi R; Parodi S; Fontana V; Pensa F; Casella C; Barreca A; De Palo G; Costa A; Decensi A
    Int J Cancer; 1998 Jun; 76(6):787-90. PubMed ID: 9626341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer.
    Serrano D; Baglietto L; Johansson H; Mariette F; Torrisi R; Onetto M; Paganuzzi M; Decensi A
    Clin Cancer Res; 2005 Mar; 11(5):2083-8. PubMed ID: 15756035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial.
    Torrisi R; Mezzetti M; Johansson H; Barreca A; Pigatto F; Robertson C; Decensi A
    Int J Cancer; 2000 Aug; 87(4):601-5. PubMed ID: 10918204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
    Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
    Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
    Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
    Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.
    Decensi A; Johansson H; Miceli R; Mariani L; Camerini T; Cavadini E; Di Mauro MG; Barreca A; Gonzaga AG; Diani S; Sandri MT; De Palo G; Formelli F
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1047-53. PubMed ID: 11588130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
    Formelli F
    J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer risk factors associated with insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels in healthy women: effect modification by menopausal status.
    Barnes BB; Chang-Claude J; Flesch-Janys D; Kinscherf R; Schmidt M; Slanger T; Bonaterra G; Steindorf K
    Cancer Causes Control; 2009 Dec; 20(10):1985-96. PubMed ID: 19597750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.
    Schernhammer ES; Holly JM; Pollak MN; Hankinson SE
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):699-704. PubMed ID: 15767352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum insulin-like growth factor-I and breast cancer.
    Toniolo P; Bruning PF; Akhmedkhanov A; Bonfrer JM; Koenig KL; Lukanova A; Shore RE; Zeleniuch-Jacquotte A
    Int J Cancer; 2000 Dec; 88(5):828-32. PubMed ID: 11072255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.
    Johansson H; Baglietto L; Guerrieri-Gonzaga A; Bonanni B; Mariette F; Macis D; Serrano D; Sandri MT; Decensi A
    Breast Cancer Res Treat; 2004 Nov; 88(1):63-73. PubMed ID: 15538047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.
    Lawrence JB; Conover CA; Haddad TC; Ingle JN; Reid JM; Ames MM; Suman VJ; Marks RS; Erlichman C; Hartmann LC
    Clin Cancer Res; 1997 Oct; 3(10):1713-20. PubMed ID: 9815555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.
    Schernhammer ES; Holly JM; Hunter DJ; Pollak MN; Hankinson SE
    Endocr Relat Cancer; 2006 Jun; 13(2):583-92. PubMed ID: 16728584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.
    Favoni RE; de Cupis A; Bruno S; Yee D; Ferrera A; Pirani P; Costa A; Decensi A
    Br J Cancer; 1998 Jun; 77(12):2138-47. PubMed ID: 9649125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients.
    Papadakis GZ; Mavroudis D; Georgoulias V; Souglakos J; Alegakis AK; Samonis G; Bagci U; Makrigiannakis A; Zoras O
    Growth Horm IGF Res; 2017 Apr; 33():28-34. PubMed ID: 28258988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial.
    Fairey AS; Courneya KS; Field CJ; Bell GJ; Jones LW; Mackey JR
    Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):721-7. PubMed ID: 12917202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factors and breast cancer risk in Chinese women.
    Yu H; Jin F; Shu XO; Li BD; Dai Q; Cheng JR; Berkel HJ; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):705-12. PubMed ID: 12163322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free insulin-like growth factor-I and breast cancer risk.
    Li BD; Khosravi MJ; Berkel HJ; Diamandi A; Dayton MA; Smith M; Yu H
    Int J Cancer; 2001 Mar; 91(5):736-9. PubMed ID: 11267989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.
    Decensi A; Bonanni B; Baglietto L; Guerrieri-Gonzaga A; Ramazzotto F; Johansson H; Robertson C; Marinucci I; Mariette F; Sandri MT; Daldoss C; Bianco V; Buttarelli M; Cazzaniga M; Franchi D; Cassano E; Omodei U
    Clin Cancer Res; 2004 Jul; 10(13):4389-97. PubMed ID: 15240527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma.
    Sheikh MS; Shao ZM; Li XS; Ordonez JV; Conley BA; Wu S; Dawson MI; Han QX; Chao WR; Quick T
    Carcinogenesis; 1995 Oct; 16(10):2477-86. PubMed ID: 7586155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.